Phase 1/2 trial of brigatinib plus panitumumab in patients with osimertinib-resistant EGFR-mutated non-small cell lung cancer harboring EGFR C797S mutation

Background: Osimertinib is a standard treatment for advanced EGFR-mutated non-small cell lung cancer (NSCLC). The EGFR C797S mutation is one of the most common resistant mechanisms to osimertinib. Based on our preclinical data, the safety and efficacy of brigatinib combined with panitumumab was eval...

Полное описание

Библиографические подробности

Главные авторы:	Hiroki Izumi, Tomohiro Sakamoto, Ken Uchibori, Kazumi Nishino, Jun Sakakibara-Konishi, Ryohei Katayama, Shogo Nomura, Shingo Matsumoto, Hibiki Udagawa, Yuji Shibata, Tetsuya Sakai, Kaname Nosaki, Yoshitaka Zenke, Kiyotaka Yoh, Seiji Niho, Koichi Goto
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Elsevier 2026-01-01
Серии:	Cancer Treatment and Research Communications
Предметы:	EGFR mutation Osimertinib Acquired resistance C797S Brigatinib Panitumumab
Online-ссылка:	http://www.sciencedirect.com/science/article/pii/S2468294226000146
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!